Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $669,280.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.80, for a total value of $854,400.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded up $1.56 during trading on Friday, hitting $84.86. The stock had a trading volume of 786,150 shares, compared to its average volume of 771,175. The firm has a fifty day moving average of $93.19 and a two-hundred day moving average of $92.84. The company has a market capitalization of $10.58 billion, a PE ratio of -18.45 and a beta of 0.94. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the business earned ($0.91) EPS. On average, equities analysts expect that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter valued at $27,000. Blue Trust Inc. raised its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Quest Partners LLC purchased a new stake in Vaxcyte during the 2nd quarter worth about $70,000. Meeder Asset Management Inc. boosted its stake in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte during the 3rd quarter valued at about $92,000. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on PCVX shares. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.